イピリムマブ（遺伝子組換え）

イピリムマブ（遺伝子組換え） 化学特性,用途語,生産方法

• 解説

  イピリムマブは，免疫チェックポイント阻害剤の一つ。T細胞の表面に発現して免疫反応を抑制するCTLA-4という受容体と結合し、がん細胞に対する攻撃力を回復させる。商品名ヤーボイ。→ニボルマブ

  小学館 デジタル大辞泉について　情報 | 凡例
  

• 説明

  Ipilimumab is a CTLA-4 blocking antibody that was approved by the U.S. FDA in March 2011 for the treatment of unresectable or metastatic melanoma. Therefore, ipilimumab has an indirect effect on tumors that is mediated through blockade of CTLA-4 negative signaling and augmentation of T-cell activity. It is one of a handful of immunostimulatory drugs (e.g., aldesleukin and interferon alfa-2b) now approved for cancer therapy.

• 使用

  Treatment of oncology disease and HIV infection.

• 副作用

  The more common side effects of ipilimumab include Bloody, black, or tarry stools; bone pain; chest pain or tightness; constipation; cough; depressed mood; diarrhea; dry skin and hair; feeling cold; fever; hair loss; heartburn; hoarseness or husky voice; indigestion; itching, skin rash; muscle cramps; nausea; pain in the arms or legs; severe stomach pain, cramping, or burning; slowed heartbeat; sneezing; sore throat; trouble breathing; unusual tiredness or weakness; vomiting; vomiting of material that looks like coffee grounds, severe and continuing; watery or bloody diarrhea.

イピリムマブ（遺伝子組換え） 生産企業

Global(70)Suppliers

477202-00-9, イピリムマブ（遺伝子組換え） キーワード